![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQC-Vczhqz-LQbzJvHNNQjXdTvsY9VtnYLaI10xtDPyrBTktttRL87KqXMjIfgKQY1oyFBzSkyLlKzy8b83Hjku5mjHyIeRlH90WeY-hf-4HjDhF_TqlO_XNWI3P7iu-CikZZilKR2mVGU/s320/domainnamelogo.jpg)
London, 19 March 2009
Doc. Ref. EMEA/177056/2009
PRESS RELEASE
Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for Ixempra (ixabepilone)
The European Medicines Agency has been formally notified by Bristol-Myers Squibb Pharma EEIG of its decision to withdraw the application for a centralised marketing authorisation for Ixempra (ixabepilone), 2 mg/ml powder and solvent for concentrate for solution for infusion.
abrir aquí para acceder al documento completo:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Ixempra
No hay comentarios:
Publicar un comentario